24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Diabetes Treatment Failure May Actually Be NonadherenceArtificial Intelligence Can Detect Diabetic RetinopathyMore Than 1 in 10 Patients May Be Overtreated for DiabetesPioglitazone Has Limited Effect in Lipoatrophic DiabetesFracture Risk Higher for Seniors With DiabetesCGM Use in Pregnancy Improves Neonatal OutcomesClosed-Loop Control Benefits T1DM in Prolonged Winter SportHeath Tip: Dining Out If You Have DiabetesExenatide Doesn't Up Cardiovascular Risk in T2DMIncreasing Salt Intake Tied to Diabetes RiskSotagliflozin Linked to Improved Glycemic Control in T1DMGreater Awareness Needed for Potential of T2DM RemissionCan Coffee or Tea Extend Survival With Diabetes?Could Artificial Sweeteners Raise Your Diabetes Risk?Could Swine Flu Be Linked to Type 1 Diabetes?'Upside' to Diabetes Really Isn'tLifestyle Tips for Better Diabetes ControlDiabetes Threatens Kidneys, Vision of Millions of Americans2017 Standards of Medical Care in Diabetes ReleasedBiomarkers Can Predict Rapid Drop in Renal Function in T2DMMany Teens With Type 1 Diabetes Report Disordered EatingCognitive Test Predicts Elderly Insulin Injection SuccessHigher Event Rate of T2DM in Polycystic Ovary SyndromeNovel Genetic Variant in IGF2 Linked to Reduced T2DM RiskFatty Acid Remodeling Seen in T2DM Remission Post Bariatric SxDiacerein Reduces Mean Hemoglobin A1c Levels in T2DMHealth Tip: Risk Factors for PrediabetesTablet Use Encourages Patients to Explore Diabetes RiskOnce-Yearly Counseling Tied to More Physical Activity in T2DMIn T2D, Glycemic Control Up With Continuous Glucose MonitoringSecure Messaging Linked to Better Diabetes ManagementStudies Often Fail to Include Info on T2DM Medication AdherenceIntensive Blood Pressure Tx Aids Those With PrediabetesLifestyle Intervention Only Offers Modest Benefit in Type 2 DiabetesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes?Variation in Participation in Diabetes Self-Management ClassTeam-Based Online Game May Improve Glycemic Control in T2DArtificial Sweeteners Trick the Brain: StudyCharacteristics of Diabetes in Infancy ExploredImmunotherapy Shown Safe in Type 1 Diabetes Clinical TrialOnline Game Helps Those With Diabetes Control Blood SugarHeart Health Ignored by Many With Type 2 DiabetesMortality Down Only for Gastric Bypass Patients With DiabetesInstagram Shows How Diabetics Really Wear a Glucose MonitorWhat Diabetics Need to Know About Over-the-Counter MedsEngineered Skin Cells Control Type 2 Diabetes in Mice: StudySimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesDiabetes Symptoms Appear to Spread Via Prion-Like MechanismPoor Adherence to Self-Monitoring of Glucose in GDM
Links
Related Topics

Medical Disorders

Plasma Uric Acid Lowering Tied to Drop in Systolic BP in T1DM


HealthDay News
Updated: Apr 26th 2017

new article illustration

WEDNESDAY, April 26, 2017 (HealthDay News) -- Lowering of plasma uric acid (PUA) with febuxostat (FBX) is associated with a modest reduction in systolic blood pressure (BP) in patients with type 1 diabetes mellitus (T1DM), according to a study published online April 13 in Diabetes.

Yuliya Lytvyn, Ph.D., from the University of Toronto, and colleagues examined the impact of PUA lowering on renal and vascular function in 49 patients with uncomplicated T1DM. Participants were assessed under eu- and hyperglycemic conditions at baseline and after PUA lowering with FBX for eight weeks. Twenty-four healthy controls were assessed under normoglycemic conditions.

The researchers found that FBX had a modest impact in terms of lowering systolic BP in patients with T1DM (112 ± 10 to 109 ± 9 mm Hg; P = 0.049), with no impact on arterial stiffness, flow and nitroglycerin mediated dilation, or urinary nitric oxide (NO). In patients with T1DM, FBX enhanced the filtration fraction response to hyperglycemia through larger increases in efferent arteriolar resistance (RE) and glomerular hydrostatic pressure, with no impact on the renin angiotensin aldosterone system (RAAS).

"FBX lowered systolic BP and modulated the renal RE responses to hyperglycemia, but without impacting the RAAS or NO, suggesting that PUA may augment other hemodynamic or inflammatory mechanisms that control the renal response to hyperglycemia at the efferent arteriole," the authors write. "Ongoing outcome trials will determine cardiorenal outcomes of PUA lowering in patients with T1D."

Takeda provided the study medications free of charge.

Abstract/Full Text (subscription or payment may be required)